PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Mutations in the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway are freqcuently found in breast...

Full description

Saved in:
Bibliographic Details
Published in:Cancer and metastasis reviews 2016-12, Vol.35 (4), p.515-524
Main Authors: Guerrero-Zotano, Angel, Mayer, Ingrid A., Arteaga, Carlos L.
Format: Article
Language:English
Subjects:
Animals
Antimitotic agents
Antineoplastic agents
Biomedical and Life Sciences
Biomedicine
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - enzymology
Cancer Research
Cellular signal transduction
Development and progression
Drug resistance
Drug Resistance, Neoplasm
Drug therapy
Female
Humans
Medical colleges
Oncogene Protein v-akt - metabolism
Oncology
Phosphatidylinositol 3-Kinases - metabolism
Physiological aspects
TOR Serine-Threonine Kinases - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Mutations in the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway are freqcuently found in breast cancers and associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK/mTOR are currently in clinical trials, mainly in combination with endocrine therapy and anti-HER2 therapy. These drugs are the focus of this review.
ISSN:0167-7659
1573-7233
DOI:10.1007/s10555-016-9637-x